UTHR Q4 2025 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$790M+7.4% YoY

Gross Profit

$687M86.9% margin

Operating Income

$357M45.1% margin

Net Income

$364M46.1% margin

EPS (Diluted)

$7.66

QoQ Revenue Growth

-1.2%

Cash Flow

Operating Cash Flow

$346M

Free Cash Flow

$173M

Stock-Based Comp.

$39M

Balance Sheet

Total Assets

$7.9B

Total Liabilities

$784M

Stockholders' Equity

$7.1B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$790M	$736M	+7.4%
Gross Profit	$687M	$660M	+4.1%
Operating Income	$357M	$358M	-0.3%
Net Income	$364M	$301M	+20.9%

Revenue Segments

Tyvaso

$464M59%

Remodulin

$128M16%

Orenitram

$121M15%

Unituxin

$62M8%

Adcirca

$8M1%

Product and Service, Other

$7M1%

Geographic Segments

UNITED STATES

$753M95%

Non-US

$37M5%